DelveInsight’s, “Endothelial PAS Domain-Containing Protein 1 Inhibitors – Pipeline Insight, 2022,” report provides comprehensive insights about 7+ companies and 7+ pipeline drugs in Endothelial PAS Domain-Containing Protein 1 Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Endothelial PAS Domain-Containing Protein 1 Inhibitors: Overview
Endothelial PAS domain-containing protein 1 (EPAS1, also known as hypoxia-inducible factor-2alpha (HIF-2alpha)) is a protein that is encoded by the EPAS1 gene in mammals. It is a type of hypoxia-inducible factor, a group of transcription factors involved in the physiological response to oxygen concentration. The gene is active under hypoxic conditions. It is also important in the development of the heart, and for maintaining the catecholamine balance required for protection of the heart. Mutation often leads to neuroendocrine tumors. This gene encodes a transcription factor involved in the induction of genes regulated by oxygen, which is induced as oxygen levels fall. The encoded protein contains a basic-helix-loop-helix domain protein dimerization domain as well as a domain found in proteins in signal transduction pathways which respond to oxygen levels. Mutations in this gene are associated with erythrocytosis familial type 4. Several drugs inhibiting EPAS1 are under clinical trials to treat several indications including renal cell carcinoma and glioblastoma.
"Endothelial PAS Domain-Containing Protein 1 Inhibitors - Pipeline Insight, 2022" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Endothelial PAS Domain-Containing Protein 1 Inhibitors pipeline landscape is provided which includes the disease overview and Endothelial PAS Domain-Containing Protein 1 Inhibitors treatment guidelines. The assessment part of the report embraces, in depth Endothelial PAS Domain-Containing Protein 1 Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Endothelial PAS Domain-Containing Protein 1 Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
The companies and academics are working to assess challenges and seek opportunities that could influence Endothelial PAS Domain-Containing Protein 1 Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve Endothelial PAS Domain-Containing Protein 1 Inhibitors.
This segment of the Endothelial PAS Domain-Containing Protein 1 Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Endothelial PAS Domain-Containing Protein 1 Inhibitors Emerging Drugs
Belzutifan: Merck & Co.,
Belzutifan (previously PT2977 and MK-6482) binds to and inhibits HIF-2α function, and has been developed as a novel cancer therapeutic. HIF-2α is a transcription factor component that is established as an oncogneic driver of ccRCC, via loss of its interaction with the tumour suppressor von Hippel-Lindau (VHL), which results in disrupted proteasomal degradation and thereby accumulation of HIF-2α. Belzutifan received FDA approval for the treatment of select VHL-associated cancers on August 13, 2021. It is currently being evaluated in Phase III stage of development for the treatment of Renal cell carcinoma and in Phase II trial to treat Biliary cancer; Colorectal cancer; Liver cancer.
PT2385: Peloton Therapeutics
PT2385 is the first clinical stage antagonist of hypoxia inducible factor-2a (HIF-2a), a transcription factor implicated in the development and progression of renal cancer. It is currently being evaluated in Phase II clinical trials to treat glioblastoma and renal cell carcinoma. In May 2019, Merck and Peloton therapeutics have entered into a definitive agreement under which Merck, through a subsidiary, will acquire privately held Peloton, a clinical-stage biopharmaceutical company focused on the development of novel small molecule therapeutic candidates targeting hypoxia-inducible factor-2α (HIF-2α) for the treatment of patients with cancer and other non-oncology diseases.
Further product details are provided in the report……..
This segment of the report provides insights about the different Endothelial PAS Domain-Containing Protein 1 Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
There are approx. 7+ key companies which are developing the therapies for Endothelial PAS Domain-Containing Protein 1 Inhibitors. The companies which have their Endothelial PAS Domain-Containing Protein 1 Inhibitors drug candidates in the most advanced stage, i.e. phase III include Merck & Co,.
DelveInsight’s report covers around 7+ products under different phases of clinical development like
Endothelial PAS Domain-Containing Protein 1 Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Products have been categorized under various Molecule types such as
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Endothelial PAS Domain-Containing Protein 1 Inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Endothelial PAS Domain-Containing Protein 1 Inhibitors drugs.
Current Treatment Scenario and Emerging Therapies:
Introduction
Executive Summary
Endothelial PAS Domain-Containing Protein 1 Inhibitors: Overview
Pipeline Therapeutics
Therapeutic Assessment
Late Stage Products (Phase III)
Belzutifan: Merck & Co.,
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
PT2385: Peloton Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Endothelial PAS Domain-Containing Protein 1 Inhibitors Key Companies
Endothelial PAS Domain-Containing Protein 1 Inhibitors Key Products
Endothelial PAS Domain-Containing Protein 1 Inhibitors- Unmet Needs
Endothelial PAS Domain-Containing Protein 1 Inhibitors- Market Drivers and Barriers
Endothelial PAS Domain-Containing Protein 1 Inhibitors- Future Perspectives and Conclusion
Endothelial PAS Domain-Containing Protein 1 Inhibitors Analyst Views
Endothelial PAS Domain-Containing Protein 1 Inhibitors Key Companies
Appendix
List of Table
Table 1: Total Products for Endothelial PAS Domain-Containing Protein 1 Inhibitors
Table 2: Late Stage Products
Table 3: Mid Stage Products
Table 4: Early Stage Products
Table 5: Pre-clinical & Discovery Stage Products
Table 6: Assessment by Product Type
Table 7: Assessment by Stage and Product Type
Table 8: Assessment by Route of Administration
Table 9: Assessment by Stage and Route of Administration
Table 10: Assessment by Molecule Type
Table 11: Assessment by Stage and Molecule Type
Table 12: Inactive Products
List of Figures
Figure 1: Total Products for Endothelial PAS Domain-Containing Protein 1 Inhibitors
Figure 2: Late Stage Products
Figure 3: Mid Stage Products
Figure 4: Early Stage Products
Figure 5: Preclinical and Discovery Stage Products
Figure 6: Assessment by Product Type
Figure 7: Assessment by Stage and Product Type
Figure 8: Assessment by Route of Administration
Figure 9: Assessment by Stage and Route of Administration
Figure 10: Assessment by Molecule Type
Figure 11: Assessment by Stage and Molecule Type
Figure 12: Inactive Products
• Merck Sharp & Dohme
• Schrodinger
• Emerald Health Pharmaceuticals
• Peloton Therapeutics
• Arrowhead Pharmaceuticals
• Arcus Bioscience
• NiKang Therapeutics
• Novartis Pharmaceuticals
